How MPNST genomic alterations affect therapy resistance is currently unclear

How MPNST genomic alterations affect therapy resistance is currently unclear. models recapitulated an MET-addicted state (NF1-MET), P53 mutation (NF1-P53), and HGF overexpression (NF1). Following perturbation with the drug, we observed broad and redundant kinome adaptations that extended well beyond canonical RAS/ERK or PI3K/AKT/mTOR signaling. MET and MEK inhibition were both associated with an initial inflammatory … Continue reading How MPNST genomic alterations affect therapy resistance is currently unclear